Glycosyn is Biotechnology in United States that focus on infectious diarrhea business. Founded in 2002. They cover business area such as manufacturer, developer, product, unique bioactive sugar, human milk, hMOS, health benefit, immune function, positive impact, overall intestinal health, serious condition, infant, childhood, adult, infectious diarrhea, inflammatory bowel disease, irritable bowel syndrome, metabolic disease, patient, risk, infection.
2002
( 22 years old in 2024 )
Infectious Diarrhea
-
890 Winter Street
Suite 208
Woburn, MA 02451
United States
Private
manufacturerdeveloperproductunique bioactive sugarhuman milkhMOShealth benefitimmune functionpositive impactoverall intestinal healthserious conditioninfantchildhoodadultinfectious diarrheainflammatory bowel diseaseirritable bowel syndromemetabolic diseasepatientriskinfection
* We use standard office opening hours in near Glycosyn's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Glycosyn is Biotechnology business from United States that founded in 2002 (22 years old in 2024), Glycosyn business is focusing on Infectious Diarrhea.
Glycosyn headquarter office and corporate office address is located in 890 Winter Street Suite 208 Woburn, MA 02451 United States.
Glycosyn was founded in United States.
In 2024, Glycosyn is currently focus on infectious diarrhea sector.
Above is snippet of Google Trends for "infectious diarrhea" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Glycosyn, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
